Last week s new deal between Aradigm Corp. and existing partner United Therapeutics Corp. through its wholly owned subsidiary Lung Rx Inc. to develop Remodulin (treprostinil) using the former s AERx Essence approach could provide the needed boost to put prostacyclins at the forefront of pulmonary arterial hypertension therapy (PAH), thanks to the metered-dose inhaler.